0000000000918002

AUTHOR

Fabrizio Bossa

showing 20 related works from this author

Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study

2020

Abstract Background Few data exist regarding the long‐term effectiveness of golimumab in ulcerative colitis. No data have been reported on real‐world continuous clinical response. Objective This study aimed to describe the long‐term outcomes in a large cohort of patients on golimumab who had ulcerative colitis. Methods Consecutive patients with active ulcerative colitis, started on golimumab, were enrolled and prospectively followed up. The primary end point was to evaluate the long‐term persistence on golimumab therapy. Results A total of 173 patients with ulcerative colitis were studied. Of these, 79.2% were steroid dependent, and 46.3% were naïve to anti‐tumour necrosis factor alpha agen…

AdultMalemedicine.medical_specialtyAdolescentnaïveGolimumabPersistence (computer science)03 medical and health sciencesYoung Adult0302 clinical medicineremissionGastrointestinal AgentsInternal medicinemedicineHumansProspective StudiesAgedRetrospective Studiesulcerative colitisbusiness.industryTumor Necrosis Factor-alphaInflammatory Bowel DiseaseGastroenterologyAntibodies MonoclonalpersistenceMiddle Agedmedicine.diseaseUlcerative colitisGolimumabGolimumab; naïve; persistence; remission; ulcerative colitisOncology030220 oncology & carcinogenesis030211 gastroenterology & hepatologyColitis UlcerativeFemaleOriginal Articlebusinessmedicine.drugFollow-Up StudiesIBD Ulcerative colitis Golimumab TNF-inhibitors
researchProduct

Infliximab in the treatment of Crohn's disease: Predictors of response in an Italian multicentric open study

2005

Abstract Background. Almost 20% of patients with active Crohn's disease are refractory to conventional therapy. Infliximab is a treatment of proven efficacy in this group of patients and it is not clear which variables predict a good response. Aims. To evaluate the role of infliximab looking at the predictors of response in a large series of patients with Crohn's disease. Patients and methods. Five hundred and seventy-three patients with luminal refractory Crohn's disease (Crohn's Disease Activity Index (CDAI) > 220–400) (312 patients) or with fistulising disease (190 patients) or both of them (71 patients) were treated with a dose of 5 mg/kg in 12 Italian referral centres. The primary endp…

AdultMalemedicine.medical_specialtyFistulaPredictors of responseAge at diagnosisDiseaseGastroenterologyAntibodiesDose-Response RelationshipCrohn DiseaseGastrointestinal AgentsRefractoryInternal medicineMonoclonalmedicineHumansinfliximab.crohn's disease.Settore MED/12 - GastroenterologiaCrohn's diseaseDose-Response Relationship DrugHepatologybusiness.industryRemission InductionSmokingGastroenterologyAntibodies Monoclonalmedicine.diseaseCrohn's Disease Activity IndexInfliximabInfliximabSurgeryOpen studyCrohn's diseaseCrohn's disease; Infliximab; Predictors of response; Adult; Antibodies Monoclonal; Crohn Disease; Dose-Response Relationship Drug; Female; Fistula; Gastrointestinal Agents; Humans; Infliximab; Italy; Male; Multivariate Analysis; Remission Induction; SmokingItalyConcomitantMultivariate AnalysisFemaleCrohn's disease; Infliximab; Predictors of responseDrugbusinessmedicine.drugDigestive and Liver Disease
researchProduct

The Italian clinical experience with adalimumab in Crohn's disease: Eleven clinical cases

2010

Crohn's diseasemedicine.medical_specialtyHepatologybusiness.industryInternal medicineGastroenterologymedicinePhysical therapyAdalimumabmedicine.diseasebusinessmedicine.drugDigestive and Liver Disease Supplements
researchProduct

P621 Efficacy and safety of golimumab in ulcerative colitis. Preliminary data from a multicenter Italian study

2017

medicine.medical_specialtyPancolitisTumor necrosis factorsbusiness.industryGastroenterologyGeneral Medicinemedicine.diseaseUlcerative colitisGolimumab03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisInternal medicinemedicine030211 gastroenterology & hepatologyPredictor variableColitismedicine.symptombusinessmedicine.drugJournal of Crohn's and Colitis
researchProduct

Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory …

2011

See related article, Oostlander AE et al, on page 116 in Gastroenterology. BACKGROUND & AIMS: Few data are available on effects of biologic therapies in patients more than 65 years old with inflammatory bowel disease (IBD). We evaluated the risk and benefits of therapy with tumor necrosis factor (TNF) inhibitors in these patients. METHODS: We collected data from patients with IBD treated with infliximab (n 2475) and adalimumab (n 604) from 2000 to 2009 at 16 tertiary centers. Ninety-five patients (3%) were more than 65 years old (52 men; 37 with ulcerative colitis and 58 with Crohn’s disease; 78 treated with infliximab and 17 with adalimumab). The control group comprised 190 patients 65 yea…

MaleAgingSettore MED/09 - Medicina InternaBiologicantagonists /&/ inhibitors/immunology Young AdultInflammatory bowel diseaseHumanized AntibodieElderlyNeoplasmsMonoclonalYoung adultAged 80 and overSettore MED/12 - GastroenterologiaCrohn's diseaseGastroenterologyAge FactorsAntibodies MonoclonalMiddle AgedUlcerative colitisepidemiology Opportunistic InfectionFemaleDrug ComplicationSafetymedicine.drugAdultmedicine.medical_specialtyAdolescentIBDOpportunistic InfectionsAntibodies Monoclonal HumanizedYoung AdultInternal medicinemedicineAdalimumab80 and over AntibodieHumansImmunologic FactorsRisk factoradverse effects/therapeutic use Inflammatory Bowel DiseaseAgedHepatologymortality/therapy Male Middle Aged Neoplasmepidemiology Tumor Necrosis Factor-alphabusiness.industryTumor Necrosis Factor-alphaAdalimumabmedicine.diseaseInflammatory Bowel DiseasesCrohn's Disease Activity IndexInfliximabInfliximabSurgeryInflammation Side Effects Drug ComplicationsSide Effectinflammationadverse effects/therapeutic use Female Humans Immunologic FactorAdolescent Adult Age Factors Aged Agedbusiness
researchProduct

Mongersen, an oral SMAD7 antisense oligonucleotide, and crohn's disease

2015

Crohn's disease-related inflammation is characterized by reduced activity of the immunosuppressive cytokine transforming growth factor β1 (TGF-β1) due to high levels of SMAD7, an inhibitor of TGF-β1 signaling. Preclinical studies and a phase 1 study have shown that an oral SMAD7 antisense oligonucleotide, mongersen, targets ileal and colonic SMAD7.In a double-blind, placebo-controlled, phase 2 trial, we evaluated the efficacy of mongersen for the treatment of persons with active Crohn's disease. Patients were randomly assigned to receive 10, 40, or 160 mg of mongersen or placebo per day for 2 weeks. The primary outcomes were clinical remission at day 15, defined as a Crohn's Disease Activit…

MaleSMAD7 antisense oligonucleotidemedicine.medical_treatmentOligonucleotidesPharmacologyPLACEBO-CONTROLLED TRIALTHERAPYGastroenterologylaw.inventionACTIVATIONImmunosuppressive AgentGlucocorticoidRandomized controlled trialCrohn DiseaselawOligonucleotideMedicineYoung adultCrohn's diseaseSettore MED/12 - GastroenterologiabiologyINDUCTIONMedicine (all)Remission InductionGeneral MedicineMiddle AgedCrohn's diseaseCytokineC-Reactive ProteinCombinationDrug Therapy CombinationFemaleDrugImmunosuppressive AgentsCOLITISHumanAdultmedicine.medical_specialtyAdolescentINFLAMMATORY-BOWEL-DISEASE PLACEBO-CONTROLLED TRIAL NECROSIS-FACTOR-ALPHA TGF-BETA-1-MEDIATED SUPPRESSION COLITIS INDUCTION ACTIVATION EFFICACY THERAPY MICEPlaceboSmad7 ProteinDose-Response RelationshipYoung AdultPharmacotherapyDouble-Blind MethodDrug TherapyInternal medicineHumansAntisenseGlucocorticoidsAgedDose-Response Relationship Drugbusiness.industryC-reactive proteinNECROSIS-FACTOR-ALPHAOligonucleotides AntisenseTGF-BETA-1-MEDIATED SUPPRESSIONEFFICACYmedicine.diseaseClinical trialMICEbiology.proteinbusinessAdolescent; Adult; Aged; C-Reactive Protein; Crohn Disease; Dose-Response Relationship Drug; Double-Blind Method; Drug Therapy Combination; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Male; Middle Aged; Oligonucleotides; Oligonucleotides Antisense; Remission Induction; Smad7 Protein; Young Adult; Medicine (all)INFLAMMATORY-BOWEL-DISEASE
researchProduct

Replication of interleukin 23 receptor and autophagy-related 16-like 1 association in adult- and pediatric-onset inflammatory bowel disease in Italy.

2008

AIM: To investigate gene variants in a large Italian inflammatory bowel disease (IBD) cohort, and to analyze the correlation of sub-phenotypes (including age at diagnosis) and epistatic interaction with other IBD genes. METHODS: Total of 763 patients with Crohn's disease (CD, 189 diagnosed at age < 19 years), 843 with ulcerative colitis (UC, 179 diagnosed < 19 years), 749 healthy controls, and 546 healthy parents (273 trios) were included in the study. The rs2241880 [autophagy-related 16-like 1 (ATG16L1)], rs11209026 and rs7517847 [interleukin 23 receptor (IL23R)], rs2066844, rs2066845, rs2066847 (CARD15), rs1050152 (OCTN1), and rs2631367 (OCTN2) gene variants were genotyped. RESULTS: The f…

AdultMaleInterleukin-23 receptorAdolescentGenotypeOrganic Cation Transport ProteinsIBDNod2 Signaling Adaptor ProteinAutophagy-Related Proteinsdigestive systemPolymorphism Single NucleotideInflammatory bowel diseaseYoung AdultSettore MED/38 - Pediatria Generale E SpecialisticaCrohn DiseaseIL23RClinical ResearchmedicineGenetic predispositionHumansGenetic Predisposition to DiseaseAge of OnsetYoung adultChildSolute Carrier Family 22 Member 5ReceptorAgedCrohn's diseaseSymportersbusiness.industryGastroenterologyInfantReceptors InterleukinGeneral MedicineMiddle AgedInflammatory Bowel Diseasesmedicine.diseaseUlcerative colitisdigestive system diseasesLogistic ModelsItalyCase-Control StudiesChild PreschoolImmunologyFemaleAge of onsetCarrier Proteinsbusiness
researchProduct

Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey

2020

Telemedicinemedicine.medical_specialtytelemedicine; COVID-19; inflammatory bowel disease; Aftercare; Betacoronavirus; Hospitalization; Humans; Infection Control; Italy; Mass Screening; Organizational Innovation; Remote Consultation; Surveys and Questionnaires; Coronavirus Infections; Hospital Units; Inflammatory Bowel Diseases; Pandemics; Pneumonia Viral; TelemedicinePneumonia ViralAftercareInflammatory bowel diseaselaw.inventionSettore MED/12Betacoronaviruslawinflammatory bowel diseaseSurveys and QuestionnairesmedicineInfection controlImmunology and AllergyHumansMass ScreeningViralLetters to the EditorPandemicsMass screeningAcademicSubjects/MED00260Remote ConsultationCOVID-19; inflammatory bowel disease; telemedicine; Aftercare; Betacoronavirus; COVID-19; Hospitalization; Humans; Infection Control; Italy; Mass Screening; Organizational Innovation; Remote Consultation; SARS-CoV-2; Surveys and Questionnaires; Coronavirus Infections; Hospital Units; Inflammatory Bowel Diseases; Pandemics; Pneumonia Viral; TelemedicineInfection Controlbusiness.industrySARS-CoV-2Remote ConsultationGastroenterologyCOVID-19PneumoniaBiological productmedicine.diseaseInflammatory Bowel DiseasesIntensive care unitOrganizational InnovationTelemedicineHospitalizationDiarrheaItalyEmergency medicinemedicine.symptomtelemedicine; COVID-19; inflammatory bowel diseasebusinessCoronavirus InfectionsHospital UnitsInflammatory Bowel Diseases
researchProduct

Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standard…

2020

BACKGROUND AND AIMS: Restructuring activities have been necessary during the lockdown phase of the coronavirus disease 2019 (COVID-19) pandemic. Few data are available on the post-lockdown phase in terms of health-care procedures in inflammatory bowel disease (IBD) care, and no data are available specifically from IBD units. We aimed to investigate how IBD management was restructured during the lockdown phase, the impact of the restructuring on standards of care and how Italian IBD units have managed post-lockdown activities. METHODS: A web-based online survey was conducted in two phases (April and June 2020) among the Italian Group for IBD affiliated units within the entire country. We inv…

Crohn’s diseasemedicine.medical_specialtystandards of careCOVID-19; Crohn’s disease; Inflammatory bowel disease; standards of care; therapy; ulcerative colitis; COVID-19; Critical Pathways; Disease Management; Humans; Inflammatory Bowel Diseases; Italy; Pandemics; Public Health Surveillance; Quality of Life; Surveys and Questionnaires; Standard of CareInflammatory bowel diseaseInflammatory bowel disease03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Public health surveillanceAmbulatory careSurveys and QuestionnairesPandemicmedicineHumansPublic Health SurveillanceDisease management (health)Intensive care medicinePandemicsulcerative colitisCrohn's diseasetherapybusiness.industryGastroenterologyDisease ManagementCOVID-19Standard of Caremedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisOncologyItalyCOVID-19; Crohn’s disease; Inflammatory bowel disease; standards of care; therapy; ulcerative colitis030220 oncology & carcinogenesisCritical PathwaysQuality of Life030211 gastroenterology & hepatologybusiness
researchProduct

Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammator…

2019

BACKGROUND Disease phenotype and outcome of late-onset Crohn's disease are still poorly defined. METHODS In this Italian nationwide multicentre retrospective study, patients diagnosed ≥65 years (late-onset) were compared with young adult-onset with 16-39 years and adult-onset Crohn's disease 40-64 years. Data were collected for 3 years following diagnosis. RESULTS A total of 631 patients (late-onset 153, adult-onset 161, young adult-onset 317) were included. Colonic disease was more frequent in late-onset (P < 0005), stenosing behaviour was more frequent than in adult-onset (P < 0003), but fistulising disease was uncommon. Surgery rates were not different between the three age groups. Syste…

MaleDiseaseConstriction PathologictumoursInflammatory bowel diseaseLate Onset DisordersCohort Studiessurgery0302 clinical medicineCrohn DiseaseLate Onset DisordersMedicineYoung adultDigestive System Surgical ProceduresCrohn's diseaseGastroenterologyIleitisMiddle AgedColitisItaly030220 oncology & carcinogenesisoutcome030211 gastroenterology & hepatologyFemaleColorectal NeoplasmsCohort studysteroidsAdultmedicine.medical_specialtyAdolescentcomorbiditieselderly03 medical and health sciencesYoung AdultInternal medicineIntestinal FistulaHumansImmunologic FactorsGlucocorticoidsAgedRetrospective StudiesPolypharmacyHepatologybusiness.industrythiopurinesRetrospective cohort studymedicine.diseasecomorbidities; elderly; outcome; steroids; surgery; thiopurines; tumoursPolypharmacyTumor Necrosis Factor Inhibitorsbusiness
researchProduct

Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study

2017

AIM To assess the impact of short infliximab (IFX) infusion on hospital resource utilization and costs. METHODS All inflammatory bowel diseases (IBD) patients who received IFX 1 h infusion from March 2007 to September 2014 in eight centers from Southern Italy were included in the analysis. Demographic, clinical and infusion related data were collected. The potential benefits related to the short infusion protocol were assessed both in terms of time saving and increased infusion unit capacity. In addition, indirect patient-related cost savings were evaluated. RESULTS One hundred and twenty-five patients were recruited (64 with ulcerative colitis and 61 with Crohn’s disease). Median duration …

musculoskeletal diseasesmedicine.medical_specialtyObservational StudyCost savings03 medical and health sciences0302 clinical medicineInternal medicinemedicineIn patient030212 general & internal medicineEconomic impact analysisskin and connective tissue diseasesProtocol (science)business.industryInflammatory Bowel DiseasesOne-hour infusionInfliximabInfliximabMulticenter studyCost savingsstomatognathic diseasesEconomic impactMulticenter studyPhysical therapy030211 gastroenterology & hepatologybusinessmedicine.drugWorld Journal of Gastrointestinal Pharmacology and Therapeutics
researchProduct

COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Ita…

2021

The coronavirus disease 2019 (COVID-19) pandemic has not finished yet, and the most promising option towards its ending is widespread vaccination. Because patients with inflammatory bowel diseases (IBDs), namely Crohn’s disease (CD) and ulcerative colitis (UC), often require immune-modifying treatment, which might increase the risk of opportunistic infection,1 their vaccination history for several infectious diseases is routinely checked, and when inadequate, vaccination is performed at diagnosis or ideally before immune suppressive treatment is started.1 However, IBD patients were not found to be at an increased risk of developing COVID-19 or of experiencing a more severe disease course.2

medicine.medical_specialty2019-20 coronavirus outbreakCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)IBDBrief Report - ClinicalInternal medicinemedicineHumansImmunology and AllergyIn patientAcademicSubjects/MED00260SARS-CoV-2business.industryVaccinationGastroenterologyCOVID-19Inflammatory Bowel DiseasesInflammatory Bowel DiseasesCOVID-19 Vaccines HumanVaccinationIBD Crohn Ulcerative Colitis Vaccination Covid 19 Sars-Cov 2COVID-19; COVID-19 vaccine; IBD; vaccine hesitancyvaccine hesitancybusinessCOVID-19 vaccineInflammatory Bowel Diseases
researchProduct

P611 Outcome in ulcerative colitis after switch from subcutaneous anti-TNF to intravenous anti-TNF: A multicentre study

2018

medicine.medical_specialtybusiness.industryInternal medicineGastroenterologyMedicineTumor necrosis factor alphaGeneral Medicinebusinessmedicine.diseaseUlcerative colitisGastroenterologyJournal of Crohn's and Colitis
researchProduct

The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy.

2019

BACKGROUND We report a prospective, nationwide cohort evaluating the safety and effectiveness of CT-P13. METHODS A structured database was used to record serious adverse events (SAEs), clinical remission/response, inflammatory biomarkers (CRP and calprotectin), and endoscopic findings. RESULTS Eight hundred ten patients with inflammatory bowel disease (IBD) (452 Crohn's disease [CD]) were enrolled. Four hundred fifty-nine patients were naive to anti-TNFα (group A), 196 had a previous exposure (group B), and the remaining 155 were switched to CT-P13 (group C). All patients were included in the safety evaluation with a mean follow-up of 345 ± 215 days and a total number of 6501 infusions. One…

0301 basic medicineAdultMalemedicine.medical_specialtyAdolescentSettore MED/12 - GASTROENTEROLOGIABiosimilar; Crohn's disease; CT-P13; Inflammatory bowel disease; Inflectra; Infliximab; Remsima; Ulcerative colitis; Adolescent; Adult; Antibodies Monoclonal; Female; Follow-Up Studies; Gastrointestinal Agents; Humans; Inflammatory Bowel Diseases; Infliximab; Italy; Male; Prognosis; Prospective Studies; Young AdultInflectraInflammatory bowel diseaseInflammatory bowel diseaseAntibodies03 medical and health sciencesYoung Adult0302 clinical medicineGastrointestinal AgentsInternal medicineMonoclonalmedicineImmunology and AllergyHumansProspective StudiesRemsimaProspective cohort studyCrohn's diseasebusiness.industryCrohn's disease; ulcerative colitis; inflammatory bowel disease; Infliximab; Remsima; Inflectra; biosimilar; CT-P13BiosimilarSettore MED/09 - MEDICINA INTERNAGastroenterologyAntibodies Monoclonalmedicine.diseaseInflammatory Bowel DiseasesPrognosisUlcerative colitisInfliximabInfliximabCrohn's disease030104 developmental biologyUlcerative colitisItalyCohort030211 gastroenterology & hepatologyFemaleCalprotectinbusinessCT-P13Cohort studymedicine.drugFollow-Up StudiesInflammatory bowel diseases
researchProduct

P463 COVID-19 vaccination willingness and hesitancy in patients with Inflammatory Bowel Diseases (IBD): analysis of determinants in a national survey…

2021

Abstract Background Vaccine hesitancy, the delay in acceptance or refusal of vaccination despite its availability, represents a threat to the diffusion and lethality of infectious diseases. COVID-19 vaccination has been recommended by national and international organizations in patients with Inflammatory Bowel Diseases (IBD). The aim of the study was to evaluate COVID-19 vaccine willingness and hesitancy in a population of Italian patients with IBD, and their determinants. Methods In February 2021 an online questionnaire focused on COVID-19 vaccine was proposed to a representative sample of Italian IBD patients. Socio-demographic characteristics, IBD features, lifestyle, perception of COVID…

2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)business.industryGastroenterologyInflammatory Bowel DiseasesGeneral MedicineClinical: Therapy and Observationmedicine.diseaseInflammatory bowel diseasePoster presentationsVaccinationVaccination RefusalFamily medicineMedicineIn patientAdverse effectbusinessAcademicSubjects/MED00260Journal of Crohn's & Colitis
researchProduct

Association between previously identified disease loci at Chr 21q22 and MHC and UC in Italian population.

2009

GeneticsHepatologybiologybusiness.industryAssociation (object-oriented programming)Gastroenterologybiology.proteinMedicineUlcerative ColitisDiseasebusinessMajor histocompatibility complexItalian population
researchProduct

Bloating is associated with worse quality of life, treatment satisfaction, and treatment responsiveness among patients with constipation-predominant …

2016

Background The management of bloating is unclear and its relationship with patients' well-being and treatment satisfaction independent of other abdominal symptoms is uncharacterized. We evaluated the association of bloating with patient-reported outcomes. Methods Thirty-nine centers for functional gastrointestinal disorders joined the laxative inadequate relief survey. We enrolled 2203 consecutive outpatients with functional constipation (FC) or constipation-predominant irritable bowel syndrome (IBS-C) in two cross-sectional waves. Both wave 1 and 2 included the SF-12, the patient assessment of constipation-symptoms (PAC-SYM), and the treatment satisfaction questionnaire for medication (TSQ…

AdultMaleQuality of lifemedicine.medical_specialtyConstipationCross-sectional studyPhysiologyBloating; Chronic constipation; Functional constipation; Irritable bowel syndrome; Patient-reported outcomes; Quality of life; Treatment satisfaction; Physiology; Endocrine and Autonomic Systems; GastroenterologyBloating; Chronic constipation; Functional constipation; Irritable bowel syndrome; Patient-reported outcomes; Quality of life; Treatment satisfaction; Adult; Constipation; Cross-Sectional Studies; Female; Flatulence; Humans; Irritable Bowel Syndrome; Male; Middle Aged; Prevalence; Quality of Life; Surveys and QuestionnairesEndocrine and Autonomic System03 medical and health sciences0302 clinical medicineBloatingQuality of lifeSurveys and QuestionnairesInternal medicinePrevalencemedicineFlatulenceHumansIrritable bowel syndromePatient-reported outcomeChronic constipationSettore MED/12 - GastroenterologiaPatient-reported outcomesTreatment satisfactionBloating; Chronic constipation; Functional constipation; Irritable bowel syndrome; Patient-reported outcomes; Quality of life; Treatment satisfaction; Adult; Constipation; Cross-Sectional Studies; Female; Flatulence; Humans; Irritable Bowel Syndrome; Male; Middle Aged; Prevalence; Quality of Life; Surveys and Questionnaires; Physiology; Endocrine and Autonomic Systems; GastroenterologyEndocrine and Autonomic Systemsbusiness.industryChronic constipationBloatingSettore MED/09 - MEDICINA INTERNAGastroenterologyMiddle Agedmedicine.diseaseIrritable bowel syndromeSettore MED/18 - Chirurgia GeneraleCross-Sectional StudiesTolerability030220 oncology & carcinogenesisPhysical therapyFunctional constipationFemale030211 gastroenterology & hepatologymedicine.symptombusinessConstipationFunctional constipation
researchProduct

sj-pdf-1-ueg-10.1177_2050640620964132 - Supplemental material for Activities related to inflammatory bowel disease management during and after the co…

2020

Supplemental material, sj-pdf-1-ueg-10.1177_2050640620964132 for Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care by Simone Saibeni, Ludovica Scucchi, Gabriele Dragoni, Cristina Bezzio, Agnese Miranda, Davide Giuseppe Ribaldone, Angela Bertani, Fabrizio Bossa, Mariangela Allocca, Andrea Buda, Gianmarco Mocci, Alessandra Soriano, Silvia Mazzuoli, Lorenzo Bertani, Flavia Baccini, Erika Loddo, Antonino Carlo Privitera, Alessandro Sartini, Angelo Viscido, Laurino Grossi, Valentina Casini, Viviana Gerardi, Marta Ascolani, Mirko Di Ruscio, Giovanni Casella, Edoardo Savarino, Davide Strade…

FOS: Clinical medicineFOS: Biological sciences111199 Nutrition and Dietetics not elsewhere classifiedFOS: Health sciences110308 Geriatrics and Gerontology69999 Biological Sciences not elsewhere classified111299 Oncology and Carcinogenesis not elsewhere classified
researchProduct

Association Between Previously Identified Disease Loci At Chr12q15 and Chr1p36 and UC in Italian Population

2009

IBDDisease loci
researchProduct

sj-pdf-1-ueg-10.1177_2050640620964132 - Supplemental material for Activities related to inflammatory bowel disease management during and after the co…

2020

Supplemental material, sj-pdf-1-ueg-10.1177_2050640620964132 for Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care by Simone Saibeni, Ludovica Scucchi, Gabriele Dragoni, Cristina Bezzio, Agnese Miranda, Davide Giuseppe Ribaldone, Angela Bertani, Fabrizio Bossa, Mariangela Allocca, Andrea Buda, Gianmarco Mocci, Alessandra Soriano, Silvia Mazzuoli, Lorenzo Bertani, Flavia Baccini, Erika Loddo, Antonino Carlo Privitera, Alessandro Sartini, Angelo Viscido, Laurino Grossi, Valentina Casini, Viviana Gerardi, Marta Ascolani, Mirko Di Ruscio, Giovanni Casella, Edoardo Savarino, Davide Strade…

FOS: Clinical medicineFOS: Biological sciences111199 Nutrition and Dietetics not elsewhere classifiedFOS: Health sciences110308 Geriatrics and Gerontology69999 Biological Sciences not elsewhere classified111299 Oncology and Carcinogenesis not elsewhere classified
researchProduct